SRR810571
GTEX
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- GTEX
- cancer_type_detailed
- —
- subtype
- —
- cancer_type
- GTEX
- sex
- Female
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INTERFERON_ALPHA_RESPONSE+0.783
- INTERFERON_GAMMA_RESPONSE+0.709
- TNFA_SIGNALING_VIA_NFKB+0.635
- IL6_JAK_STAT3_SIGNALING+0.574
- INFLAMMATORY_RESPONSE+0.566
- ALLOGRAFT_REJECTION+0.534
- COMPLEMENT+0.465
- P53_PATHWAY+0.406
- IL2_STAT5_SIGNALING+0.404
- APOPTOSIS+0.394
Top 10 suppressed
- HEDGEHOG_SIGNALING-0.337
- OXIDATIVE_PHOSPHORYLATION-0.314
- PROTEIN_SECRETION-0.253
- FATTY_ACID_METABOLISM-0.205
- ADIPOGENESIS-0.192
- MITOTIC_SPINDLE-0.148
- UV_RESPONSE_DN-0.137
- BILE_ACID_METABOLISM-0.123
- KRAS_SIGNALING_DN-0.101
- SPERMATOGENESIS-0.089
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
7 twins match this tumor's tissue · 3 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR817658 | GTEX | — | 0.972 |
| 2 | SRR819346 | GTEX | — | 0.957 |
| 3 | SRR821019 | GTEX | — | 0.929 |
| 4 | SRR1445895 | GTEX | — | 0.897 |
| 5 | SRR8613765 | — | D | 0.893 |
| 6 | BS_2W3NC4K1 | Neurofibroma | — | 0.878 |
| 7 | BS_KXMYBQ6N | EPN | EPN Tumor | 0.876 |
| 8 | SRR934894 | — | — | 0.874 |
| 9 | TCGA-FD-A62N-01A-11R-A30C-07 | — | — | 0.873 |
| 10 | MDT-AP-1245 | Med | Medulloblastoma | 0.873 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 36 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_ALPHA_RESPONSE | 0.783 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.709 | Idelalisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.635 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.574 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.566 | Idelalisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.534 | Idelalisib | — uncovered |
| COMPLEMENT | 0.465 | Inavolisib | — uncovered |
| P53_PATHWAY | 0.406 | Idelalisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.404 | Idelalisib | — uncovered |
| APOPTOSIS | 0.394 | Idelalisib | — uncovered |
| COAGULATION | 0.362 | Binimetinib | — uncovered |
| HYPOXIA | 0.353 | Idelalisib | — uncovered |
| KRAS_SIGNALING_UP | 0.302 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.299 | Remibrutinib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.298 | Inavolisib | — uncovered |
| UV_RESPONSE_UP | 0.296 | Idelalisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.283 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.223 | Idelalisib | — uncovered |
| MYC_TARGETS_V2 | 0.181 | Idelalisib | — uncovered |
| DNA_REPAIR | 0.174 | Idelalisib | — uncovered |